Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Zydus Lifesciences Limited
Zydus Lifesciences makes and sells generic medicines, vaccines, and consumer health products, with most of its sales coming from the United States and India.
Zydus Lifesciences is a drugmaker. It makes copycat versions of medicines whose patents have expired — generic pills and injections sold at a fraction of the price of the original brand — and it sells them to hospitals, pharmacies, and distributors in the United States, India, and dozens of other countries. It also makes vaccines, over-the-counter remedies, and health supplements. Most of its money comes from the United States, where it sells generics, and from India, where it sells both medicines and consumer brands people pick up at the pharmacy counter.
Here is the basic economics of generics. A new drug costs hundreds of millions of dollars and years of testing to develop, and the company that invents it gets a patent that gives it a temporary monopoly and high prices. Once that patent expires, companies like Zydus can make the same chemical and sell it cheaply. Prices collapse, volume explodes, and the winners are the manufacturers with the most efficient factories. Zydus competes by owning a large portfolio of these copycat drugs, including hard-to-make injectable medicines and complex products, and by winning approval to sell them first, which earns a brief window of fat profits before other copycats pile in. The American market is the big prize and the big risk. Zydus built a large presence there through its own filings and by buying businesses, and it makes some of its money from a few products where it enjoys limited competition. When rivals get approval for those same products, prices drop sharply — that is a recurring headache for every generics maker. The company also invests in higher-margin areas, including vaccines, complex injectables, and consumer brands in India, which give it steadier income than the volatile generic pill business. In recent years it has pushed into newer, harder-to-copy products and biosimilars, the generic versions of expensive biologic drugs.
Zydus has a long history: it grew out of a family business in Ahmedabad and took the name Cadila Healthcare before rebranding as Zydus Lifesciences. The rebrand matters less than the strategy — the company uses its cash to fund research, build manufacturing capacity, pay dividends, and buy back shares. One recent buyback returned roughly a few percent of shares to investors. Its size, its global footprint, and its low-cost manufacturing base in India are its strengths; its dependence on the US generics market, where prices keep falling, is its main vulnerability.
Saved answer · last researched 12 Nov 2026